{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:38:47Z","timestamp":1792373927460,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-50526-x","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:28:13Z","timestamp":1778218093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of flat-dose versus weight-based dose nivolumab treatment in NSCLC patients"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2028-9687","authenticated-orcid":false,"given":"Muhammet","family":"Cengiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3551-5234","authenticated-orcid":false,"given":"Oktay","family":"Bozkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9133-8602","authenticated-orcid":false,"given":"Ayse Nuransoy","family":"Cengiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6924-9467","authenticated-orcid":false,"given":"Deniz Can","family":"Guven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1976-3951","authenticated-orcid":false,"given":"Elif","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1008-2527","authenticated-orcid":false,"given":"Emel Mutlu","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-4846","authenticated-orcid":false,"given":"Mustafa","family":"Ersoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-7047","authenticated-orcid":false,"given":"Ezgi","family":"Turko\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedat","family":"Yildirim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3708-2479","authenticated-orcid":false,"given":"Erdem","family":"Kolemen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8178-0277","authenticated-orcid":false,"given":"Beyza","family":"Unlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2215-5567","authenticated-orcid":false,"given":"Hayati","family":"Arvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-720X","authenticated-orcid":false,"given":"Mehmet Mutlu","family":"Kidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-0668","authenticated-orcid":false,"given":"Sedat","family":"Biter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3465-1085","authenticated-orcid":false,"given":"Latif","family":"Karahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5884-4669","authenticated-orcid":false,"given":"Mustafa","family":"Erman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4963-2028","authenticated-orcid":false,"given":"Ismail Oguz","family":"Kara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3291-8134","authenticated-orcid":false,"given":"Meltem","family":"Baykara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5310-5557","authenticated-orcid":false,"given":"Pervin Can","family":"Sanci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-266X","authenticated-orcid":false,"given":"An\u0131l","family":"Karakayali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6126-5377","authenticated-orcid":false,"given":"Umut","family":"Kefeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7871-6311","authenticated-orcid":false,"given":"Devrim","family":"Cabuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-7390","authenticated-orcid":false,"given":"Saadettin","family":"Kilickap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2749-9414","authenticated-orcid":false,"given":"Teoman","family":"Sakalar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2575-5819","authenticated-orcid":false,"given":"Nargiz","family":"Majidova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1058-5500","authenticated-orcid":false,"given":"Berrak","family":"Mermit Ercek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muslih","family":"Urun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-6483","authenticated-orcid":false,"given":"G\u00f6zde","family":"Agdas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7347-263X","authenticated-orcid":false,"given":"Duygu","family":"Bayir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3668-5550","authenticated-orcid":false,"given":"Cengiz","family":"Akosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-2904","authenticated-orcid":false,"given":"Erkam","family":"Kocaaslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-8741","authenticated-orcid":false,"given":"Havva Yesil","family":"Cinkir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1586-3868","authenticated-orcid":false,"given":"Aslihan Ezgi Apaydin","family":"Rollas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3737-3420","authenticated-orcid":false,"given":"Mevlude","family":"Inanc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0359-0504","authenticated-orcid":false,"given":"Metin","family":"Ozkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"14","key":"50526_CR1","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/1078-0432.CCR-16-0714","volume":"23","author":"JA Beaver","year":"2017","unstructured":"Beaver, J. A. et al. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin. Cancer Res. 23 (14), 3479\u20133483 (2017).","journal-title":"Clin. Cancer Res."},{"key":"50526_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-3-319-40389-2_3","volume":"170","author":"GA Woodard","year":"2016","unstructured":"Woodard, G. A., Jones, K. D. & Jablons, D. M. Lung cancer staging and prognosis. Cancer Treat. Res. 170, 47\u201375 (2016).","journal-title":"Cancer Treat. Res."},{"key":"50526_CR3","doi-asserted-by":"publisher","unstructured":"Tzschoppe, T., Ohlinger, J., Vordermark, D., Bedir, A. & Medenwald, D. Population based study on the progress in survival of primarily metastatic lung cancer patients in Germany. Sci Rep [Internet]. ;14(1):1\u201310. (2024). Available from: https:\/\/doi.org\/10.1038\/s41598-024-66307-3","DOI":"10.1038\/s41598-024-66307-3"},{"issue":"2","key":"50526_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non\u2013Small-Cell Lung Cancer. N Engl. J. Med. 373 (2), 123\u2013135 (2015).","journal-title":"N Engl. J. Med."},{"issue":"18","key":"50526_CR5","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.1158\/1078-0432.CCR-16-2842","volume":"23","author":"Y Feng","year":"2017","unstructured":"Feng, Y. et al. Nivolumab exposure\u2013response analyses of efficacy and safety in previously treated squamous or nonsquamous non\u2013small cell lung cancer. Clin. Cancer Res. 23 (18), 5394\u20135405 (2017).","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"50526_CR6","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1093\/annonc\/mdx235","volume":"28","author":"X Zhao","year":"2017","unstructured":"Zhao, X. et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg\/kg dosing regimen in patients with advanced tumors. Ann. Oncol. 28 (8), 2002\u20132008 (2017).","journal-title":"Ann. Oncol."},{"issue":"35","key":"50526_CR7","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","volume":"35","author":"L Horn","year":"2017","unstructured":"Horn, L. et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: Two-year outcomes from two randomized, open-label, phase III Trials (CheckMate 017 and CheckMate 057). J. Clin. Oncol. 35 (35), 3924\u20133933 (2017).","journal-title":"J. Clin. Oncol."},{"key":"50526_CR8","unstructured":"Food, U. S. & Drug Administration. and. Modification of the Dosage Regimen for Nivolumab [Internet]. U.S. Food and Drug Administration; (2016). Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/modification-dosage-regimen-nivolumab"},{"key":"50526_CR9","doi-asserted-by":"publisher","unstructured":"Zhou, J. et al. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol [Internet]. ;93(July):102693. (2024). Available from: https:\/\/doi.org\/10.1016\/j.canep.2024.102693","DOI":"10.1016\/j.canep.2024.102693"},{"issue":"26","key":"50526_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and Activity of Anti\u2013PD-L1 Antibody in Patients with Advanced Cancer. N Engl. J. Med. 366 (26), 2455\u20132465 (2012).","journal-title":"N Engl. J. Med."},{"key":"50526_CR11","doi-asserted-by":"publisher","unstructured":"Rajan, A., Kim, C., Heery, C. R., Guha, U. & Gulley, J. L. Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Hum Vaccines Immunother [Internet]. ;12(9):2219\u201331. (2016). Available from: https:\/\/doi.org\/10.1080\/21645515.2016.1175694","DOI":"10.1080\/21645515.2016.1175694"},{"issue":"2","key":"50526_CR12","first-page":"68","volume":"34","author":"SY Disli","year":"2024","unstructured":"Disli, S. Y., Ayas, E., Disli, A. K. & Ozdemir, F. Prognostic Value of Inflammatory and Nutritional Index in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab in Second-Line Therapy. UHOD - Uluslararasi Hematol. Derg. 34 (2), 68\u201373 (2024).","journal-title":"UHOD - Uluslararasi Hematol. Derg"},{"issue":"2","key":"50526_CR13","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.annonc.2019.10.015","volume":"31","author":"X Zhao","year":"2020","unstructured":"Zhao, X. et al. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types. Ann. Oncol. Off J. Eur. Soc. Med. Oncol. 31 (2), 302\u2013309 (2020).","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"key":"50526_CR14","doi-asserted-by":"publisher","unstructured":"Souza, I. A. D. A., Dobbert, B. D. M., Jose, B. G. S., Homse-netto, J. P. & Furlan, L. L. Low-Dose Anti-PD (L) 1 for the Treatment of Solid Malignancies. Immunotherapy [Internet]. ;10(L):e2400122. (2024). Available from: https:\/\/doi.org\/10.1200\/GO.24.00122","DOI":"10.1200\/GO.24.00122"},{"issue":"2","key":"50526_CR15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/cas.14252","volume":"111","author":"D Bei","year":"2020","unstructured":"Bei, D. et al. Benefit-risk assessment of nivolumab 240\u00a0mg flat dose relative to 3\u00a0mg\/kg Q2W regimen in Japanese patients with advanced cancers. Cancer Sci. 111 (2), 528\u2013535 (2020).","journal-title":"Cancer Sci."},{"key":"50526_CR16","doi-asserted-by":"crossref","unstructured":"Kumar, A. et al. Efficacy and Safety of Low-Dose Nivolumab in Treatment of Advanced Solid Tumors: A Retrospective Audit from Resource-Constrained Settings. South. Asian J. Cancer 14 (1), 70\u201376 (2024).","DOI":"10.1055\/s-0044-1788649"},{"issue":"5","key":"50526_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/esmoopen-2018-000332","volume":"3","author":"SH Yoo","year":"2018","unstructured":"Yoo, S. H. et al. Low-dose nivolumab can be effective in non-small cell lung cancer: Alternative option for financial toxicity. ESMO Open. 3 (5), 1\u20138 (2018).","journal-title":"ESMO Open."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50526-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50526-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50526-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T22:58:18Z","timestamp":1783897098000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-50526-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["50526"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-50526-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have read and approved the final version of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21691"}}